{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:25:05Z","timestamp":1793744705813,"version":"4.6.1"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1806225N"],"award-info":[{"award-number":["1806225N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007660","name":"Universiteit Antwerpen","doi-asserted-by":"publisher","award":["GRANT MULTPLEX"],"award-info":[{"award-number":["GRANT MULTPLEX"]}],"id":[{"id":"10.13039\/501100007660","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002913","name":"Vlaamse Overheid","doi-asserted-by":"publisher","award":["HBC.2024.0265"],"award-info":[{"award-number":["HBC.2024.0265"]}],"id":[{"id":"10.13039\/501100002913","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01544-5","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:34:28Z","timestamp":1781915668000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The search for safe and effective CAR-T targets in AML"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5176-3214","authenticated-orcid":false,"given":"Florian","family":"Van Oers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4899-8300","authenticated-orcid":false,"given":"Donovan","family":"Flumens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9924-1801","authenticated-orcid":false,"given":"Simon","family":"Haentjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0038-9947","authenticated-orcid":false,"given":"Laurens","family":"Krekelbergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1951-6715","authenticated-orcid":false,"given":"S\u00e9bastien","family":"Anguille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"key":"1544_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s40164-025-00726-4","volume":"14","author":"\u00c1 Oca\u00f1a-Cara","year":"2025","unstructured":"Oca\u00f1a-Cara \u00c1, Mutis T, van der Schans JJ. Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting. Exp Hematol Oncol. 2025;14:135.","journal-title":"Exp Hematol Oncol"},{"key":"1544_CR2","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood.2024024063","volume":"145","author":"S Haubner","year":"2025","unstructured":"Haubner S, Subklewe M, Sadelain M. Honing CAR T cells to tackle acute myeloid leukemia. Blood. 2025;145:1113\u201325.","journal-title":"Blood"},{"key":"1544_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","volume":"32","author":"F Perna","year":"2017","unstructured":"Perna F, Berman SH, Soni RK, Mansilla-Soto J, Eyquem J, Hamieh M, et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell. 2017;32:506\u201319.e5.","journal-title":"Cancer Cell"},{"key":"1544_CR4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s12185-024-03809-w","volume":"120","author":"S Saito","year":"2024","unstructured":"Saito S, Nakazawa Y. CAR-T cell therapy in AML: recent progress and future perspectives. Int J Hematol. 2024;120:455\u201366.","journal-title":"Int J Hematol"},{"key":"1544_CR5","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1182\/blood-2024-207659","volume":"144","author":"Y Lin","year":"2024","unstructured":"Lin Y, Zhao D, Deng B, Liu D, Yan H, Li B, et al. The safety and efficacy of CD33 CAR-T therapy for RR AML after HSCT. Blood. 2024;144:3467.","journal-title":"Blood"},{"key":"1544_CR6","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1200\/JCO.2024.42.16_suppl.6518","volume":"42","author":"J Pan","year":"2024","unstructured":"Pan J, Zuo S, Li C, Ling Z, Xu J, Duan J, et al. Phase I study of functionally enhanced CD33 CAR T cells in patients with relapsed or refractory acute myeloid leukemia. J Clin Oncol. 2024;42:6518.","journal-title":"J Clin Oncol"},{"key":"1544_CR7","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/j.ymthe.2025.03.052","volume":"33","author":"M Khalifeh","year":"2025","unstructured":"Khalifeh M, Hopewell E, Salman H. CAR-T cell therapy for treatment of acute myeloid leukemia, advances and outcomes. Mol Ther. 2025;33:2441\u201353.","journal-title":"Mol Ther"},{"key":"1544_CR8","doi-asserted-by":"crossref","unstructured":"Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, et al. A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT. Blood. 2026;147:1914\u201327.","DOI":"10.1182\/blood.2025031053"},{"key":"1544_CR9","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1038\/s41375-025-02767-4","volume":"39","author":"D Pollyea","year":"2025","unstructured":"Pollyea D, Kerre T, Deeren D, Beguin Y, Lin TL, Sallman DA, et al. Downregulation of MICA\/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia. Leukemia. 2025;39:2907\u201315.","journal-title":"Leukemia"},{"key":"1544_CR10","first-page":"615","volume":"12","author":"YJ Ma","year":"2022","unstructured":"Ma YJ, Dai HP, Cui QY, Cui W, Zhu WJ, Qu CJ, et al. Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment. Am J Cancer Res. 2022;12:615\u201321.","journal-title":"Am J Cancer Res"},{"key":"1544_CR11","first-page":"2024","volume":"ume 15","author":"M Zhang","year":"2025","unstructured":"Zhang M, Zhang X, Wang J, Lu W, Xiao X, Lyu H, et al. Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. Front Immunol. 2025;ume 15:2024.","journal-title":"Front Immunol"},{"key":"1544_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13045-025-01764-5","volume":"18","author":"X Zhang","year":"2025","unstructured":"Zhang X, Lu W, Zhang W, He X, Zhang Y, Jin X, et al. Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed\/refractory acute myeloid leukemia. J Hematol Oncol. 2025;18:112.","journal-title":"J Hematol Oncol"},{"key":"1544_CR13","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","volume":"390","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zhang M, Yang T, Mo Z, Wei G, Jing R, et al. Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis. N Engl J Med. 2024;390:1467\u201380.","journal-title":"N Engl J Med"},{"key":"1544_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/blood-2021-147667","volume":"138","author":"J Yang","year":"2021","unstructured":"Yang J, Zhang X, Liu Y, Yang X, Wang H, Wang L, et al. High effectiveness and safety of anti-CD7 CAR T-cell therapy in treating relapsed or refractory (R\/R) T-cell acute lymphoblastic leukemia (T-ALL). Blood. 2021;138:473.","journal-title":"Blood"},{"key":"1544_CR15","volume":"72","author":"I Danylesko","year":"2024","unstructured":"Danylesko I, Shem-Tov N, Yerushalmi R, Jacoby E, Toren A, Shouval R, et al. Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed\/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression. Curr Res Transl Med. 2024;72:103471.","journal-title":"Curr Res Transl Med"},{"key":"1544_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-025-01708-z","volume":"18","author":"J Yin","year":"2025","unstructured":"Yin J, Cui Q-Y, Dai H-P, Qu C-J, Li Z, Kang L-Q, et al. CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial. J Hematol Oncol. 2025;18:53.","journal-title":"J Hematol Oncol"},{"key":"1544_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner S, Perna F, K\u00f6hnke T, Schmidt C, Berman S, Augsberger C, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33:64\u201374.","journal-title":"Leukemia"},{"key":"1544_CR18","doi-asserted-by":"publisher","first-page":"17ra9","DOI":"10.1126\/scitranslmed.3000349","volume":"2","author":"Y Saito","year":"2010","unstructured":"Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med. 2010;2:17ra9.","journal-title":"Sci Transl Med"},{"key":"1544_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cyto.b.20368","volume":"74","author":"J Zheng","year":"2008","unstructured":"Zheng J, Wang X, Hu Y, Yang J, Liu J, He Y, et al. A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China. Cytom B Clin Cytom. 2008;74:25\u20139.","journal-title":"Cytom B Clin Cytom"},{"key":"1544_CR20","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1182\/blood.V84.4.1220.1220","volume":"84","author":"K Bradstock","year":"1994","unstructured":"Bradstock K, Matthews J, Benson E, Page F, Bishop J, Pidcock M, et al. Prognostic value of immunophenotyping in acute myeloid-leukemia. Blood. 1994;84:1220\u20135.","journal-title":"Blood"},{"key":"1544_CR21","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.1182\/bloodadvances.2020001742","volume":"4","author":"H Herrmann","year":"2020","unstructured":"Herrmann H, Sadovnik I, Eisenwort G, R\u00fclicke T, Blatt K, Herndlhofer S, et al. Delineation of target expression profiles in CD34+\/CD38- and CD34+\/CD38+ stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118\u201332.","journal-title":"Blood Adv"},{"key":"1544_CR22","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.3390\/cancers15194885","volume":"15","author":"S Madan","year":"2023","unstructured":"Madan S, Sinha S, Chang T, Gutkind JS, Cohen EEW, Sch\u00e4ffer AA, et al. Pan-cancer analysis of patient tumor single-cell transcriptomes identifies promising selective and safe chimeric antigen receptor targets in head and neck cancer. Cancers. 2023;15:4885.","journal-title":"Cancers"},{"key":"1544_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-019-0758-x","volume":"12","author":"J Wei","year":"2019","unstructured":"Wei J, Han X, Bo J, Han W. Target selection for CAR-T therapy. J Hematol Oncol. 2019;12:62.","journal-title":"J Hematol Oncol"},{"key":"1544_CR24","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","volume":"35","author":"N Daver","year":"2021","unstructured":"Daver N, Alotaibi AS, B\u00fccklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021;35:1843\u201363.","journal-title":"Leukemia"},{"key":"1544_CR25","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","volume":"41","author":"S Haubner","year":"2023","unstructured":"Haubner S, Mansilla-Soto J, Nataraj S, Kogel F, Chang Q, de Stanchina E, et al. Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell. 2023;41:1871\u201391.e6.","journal-title":"Cancer Cell"},{"key":"1544_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1615\/CritRevImmunol.2021037096","volume":"41","author":"LRC Barros","year":"2021","unstructured":"Barros LRC. In search of an ideal CAR-T cell antigen target. Crit Rev Immunol. 2021;41:69\u201376.","journal-title":"Crit Rev Immunol"},{"key":"1544_CR27","doi-asserted-by":"publisher","first-page":"6520","DOI":"10.1158\/1078-0432.CCR-05-0468","volume":"11","author":"A van Rhenen","year":"2005","unstructured":"van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005;11:6520\u20137.","journal-title":"Clin Cancer Res"},{"key":"1544_CR28","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3324\/haematol.2011.047894","volume":"96","author":"F Vergez","year":"2011","unstructured":"Vergez F, Green AS, Tamburini J, Sarry JE, Gaillard B, Cornillet-Lefebvre P, et al. High levels of CD34+CD38low\/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica. 2011;96:1792\u20138.","journal-title":"Haematologica"},{"key":"1544_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach P, Trumpp A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica. 2023;108:353\u201366.","journal-title":"Haematologica"},{"key":"1544_CR30","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"Y Hu","year":"2022","unstructured":"Hu Y, Zhou Y, Zhang M, Zhao H, Wei G, Ge W, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022;32:995\u20131007.","journal-title":"Cell Res"},{"key":"1544_CR31","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1158\/0008-5472.CAN-23-2314","volume":"84","author":"D Huang","year":"2024","unstructured":"Huang D, Yu Z, Lu H, Jiang P, Qian X, Han Y, et al. Adhesion GPCR ADGRE2 maintains proteostasis to promote progression in acute myeloid leukemia. Cancer Res. 2024;84:2090\u2013108.","journal-title":"Cancer Res"},{"key":"1544_CR32","doi-asserted-by":"publisher","first-page":"4322","DOI":"10.1182\/blood-2024-208614","volume":"144","author":"S Sendker","year":"2024","unstructured":"Sendker S, Gehlen J, Ziedrich T, Antoniou E, Schneider M, Von Neuhoff N, et al. Comprehensive analysis of target and immune checkpoint markers in pediatric AML. Blood. 2024;144:4322.","journal-title":"Blood"},{"key":"1544_CR33","doi-asserted-by":"publisher","first-page":"5259","DOI":"10.1182\/blood-2018-99-113037","volume":"132","author":"R Shahswar","year":"2018","unstructured":"Shahswar R, Kloos A, Gabdoulline R, Mohanty S, Koenecke C, Wichmann M, et al. Frequency and clinical characteristics associated with putative CAR targets ADGRE2, CCR1, CD70, and LILRB2 in acute myeloid leukemia. Blood. 2018;132:5259.","journal-title":"Blood"},{"key":"1544_CR34","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1182\/blood.2020009192","volume":"138","author":"H Jetani","year":"2021","unstructured":"Jetani H, Navarro-Bail\u00f3n A, Maucher M, Frenz S, Verbruggen C, Yeguas A, et al. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood. 2021;138:1830\u201342.","journal-title":"Blood"},{"key":"1544_CR35","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1038\/s41375-021-01188-3","volume":"35","author":"D Kovalovsky","year":"2021","unstructured":"Kovalovsky D, Yoon JH, Cyr MG, Simon S, Voynova E, Rader C, et al. Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia. Leukemia. 2021;35:2581\u201391.","journal-title":"Leukemia"},{"key":"1544_CR36","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1182\/blood.2024024104","volume":"144","author":"MJ Frigault","year":"2024","unstructured":"Frigault MJ, Graham CE, Berger TR, Ritchey J, Horick NK, El-Jawahri A, et al. Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies. Blood. 2024;144:1153\u201367.","journal-title":"Blood"},{"key":"1544_CR37","doi-asserted-by":"crossref","unstructured":"Zhang Q, Han Q, Zi J, Song C, Ge Z. CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia. Biosci Rep 2020;40:BSR20200008.","DOI":"10.1042\/BSR20200008"},{"key":"1544_CR38","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1182\/blood-2012-09-458935","volume":"121","author":"M Askmyr","year":"2013","unstructured":"Askmyr M, \u00c5gerstam H, Hansen N, Gordon S, Arvanitakis A, Rissler M, et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood. 2013;121:3709\u201313.","journal-title":"Blood"},{"key":"1544_CR39","doi-asserted-by":"crossref","unstructured":"Trad R, Warda W, Alcazer V, Neto da Rocha M, Berceanu A, Nicod C, et al. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia. J Immunother Cancer. 2022;10:e004222.","DOI":"10.1136\/jitc-2021-004222"},{"key":"1544_CR40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-024-01586-x","volume":"17","author":"Zhang","year":"2024","unstructured":"Zhang, Park Y, Ghoda LY M, Zhao D, Valerio M, Nafie E, et al. IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells. J Hematol Oncol. 2024;17:67.","journal-title":"J Hematol Oncol"},{"key":"1544_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13045-025-01755-6","volume":"18","author":"K Harada","year":"2025","unstructured":"Harada K, Zhao D, Park M, Chen F, Xu Y, Zhang Y, et al. MicroRNA-142 improves IL1RAP CAR-T cell activity in acute myeloid leukemia. J Hematol Oncol. 2025;18:99.","journal-title":"J Hematol Oncol"},{"key":"1544_CR42","first-page":"6846","volume":"61","author":"P Brossart","year":"2001","unstructured":"Brossart P, Schneider A, Dill P, Schammann T, Gr\u00fcnebach F, Wirths S, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 2001;61:6846\u201350.","journal-title":"Cancer Res"},{"key":"1544_CR43","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.exphem.2008.04.015","volume":"36","author":"S Fatrai","year":"2008","unstructured":"Fatrai S, Schepers H, Tadema H, Vellenga E, Daenen SM, Schuringa JJ. Mucin1 expression is enriched in the human stem cell fraction of cord blood and is upregulated in majority of the AML cases. Exp Hematol. 2008;36:1254\u201365.","journal-title":"Exp Hematol"},{"key":"1544_CR44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.exphem.2018.12.002","volume":"70","author":"T Guillaume","year":"2019","unstructured":"Guillaume T, Dehame V, Chevallier P, Peterlin P, Garnier A, Gr\u00e9goire M, et al. Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies. Exp Hematol. 2019;70:97\u2013108.","journal-title":"Exp Hematol"},{"key":"1544_CR45","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.1158\/0008-5472.CAN-13-0677","volume":"73","author":"D Stroopinsky","year":"2013","unstructured":"Stroopinsky D, Rosenblatt J, Ito K, Mills H, Yin L, Rajabi H, et al. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Res. 2013;73:5569\u201379.","journal-title":"Cancer Res"},{"key":"1544_CR46","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1080\/00313020310001602576","volume":"35","author":"CF Leong","year":"2003","unstructured":"Leong CF, Raudhawati O, Cheong SK, Sivagengei K, Noor Hamidah H. Epithelial membrane antigen (EMA) or MUC1 expression in monocytes and monoblasts. Pathology. 2003;35:422\u20137.","journal-title":"Pathology"},{"key":"1544_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.846310","volume":"13","author":"A Gilchrist","year":"2022","unstructured":"Gilchrist A, Echeverria SL. Targeting chemokine receptor CCR1 as a potential therapeutic approach for multiple myeloma. Front Endocrinol. 2022;13:846310.","journal-title":"Front Endocrinol"},{"key":"1544_CR48","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1182\/blood-2023-184464","volume":"142","author":"S Chen","year":"2023","unstructured":"Chen S, Boardman AP, James SE, van den Brink MRM. CCR1-targeting CAR T cells for acute myeloid leukemia. Blood. 2023;142:4808.","journal-title":"Blood"},{"key":"1544_CR49","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1182\/blood.2023022992","volume":"143","author":"S Mensurado","year":"2024","unstructured":"Mensurado S, Conde\u00e7o C, S\u00e1nchez-Mart\u00ednez D, Shirley S, Coelho RML, Tirado N, et al. CD155\/PVR determines acute myeloid leukemia targeting by Delta One T cells. Blood. 2024;143:1488\u201395.","journal-title":"Blood"},{"key":"1544_CR50","first-page":"1107","volume":"109","author":"Y Kaito","year":"2024","unstructured":"Kaito Y, Sugimoto E, Nakamura F, Tsukune Y, Sasaki M, Yui S, et al. Immune checkpoint molecule DNAM-1\/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia. Haematologica. 2024;109:1107\u201320.","journal-title":"Haematologica"},{"key":"1544_CR51","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1038\/s41388-018-0288-y","volume":"37","author":"H Stamm","year":"2018","unstructured":"Stamm H, Klingler F, Grossjohann EM, Muschhammer J, Vettorazzi E, Heuser M, et al. Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. Oncogene. 2018;37:5269\u201380.","journal-title":"Oncogene"},{"key":"1544_CR52","doi-asserted-by":"crossref","unstructured":"Xiong T, Wang G, Yu P, Li Z, Li D, Zhang J, et al. CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors. J Clin Invest. 2025.","DOI":"10.1172\/JCI189920"},{"key":"1544_CR53","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","volume":"562","author":"M Deng","year":"2018","unstructured":"Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562:605\u20139.","journal-title":"Nature"},{"key":"1544_CR54","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cyto.b.21050","volume":"84","author":"H Dobrowolska","year":"2013","unstructured":"Dobrowolska H, Gill KZ, Serban G, Ivan E, Li Q, Qiao P, et al. Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation. Cytom B Clin Cytom. 2013;84:21\u20139.","journal-title":"Cytom B Clin Cytom"},{"key":"1544_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106480","volume":"100","author":"CP Bergstrom","year":"2021","unstructured":"Bergstrom CP, Dahiya S, Chen W, Zhang CC, Zhu H, Yan J, et al. The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement. Leuk Res. 2021;100:106480.","journal-title":"Leuk Res"},{"key":"1544_CR56","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cyto.b.21952","volume":"100","author":"HRO Churchill","year":"2021","unstructured":"Churchill HRO, Fuda FS, Xu J, Deng M, Zhang CC, An Z, et al. Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation. Cytom B Clin Cytom. 2021;100:476\u201387.","journal-title":"Cytom B Clin Cytom"},{"key":"1544_CR57","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","volume":"26","author":"S John","year":"2018","unstructured":"John S, Chen H, Deng M, Gui X, Wu G, Chen W, et al. A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML. Mol Ther. 2018;26:2487\u201395.","journal-title":"Mol Ther"},{"key":"1544_CR58","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/tpj.2017.46","volume":"18","author":"DI Staquicini","year":"2018","unstructured":"Staquicini DI, D\u2019Angelo S, Ferrara F, Karjalainen K, Sharma G, Smith TL, et al. Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in vitro and formal toxicity study of BMTP-78 in rodents and primates. Pharmacogenomics J. 2018;18:436\u201343.","journal-title":"Pharmacogenomics J"},{"key":"1544_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28243-6","volume":"13","author":"N Hebbar","year":"2022","unstructured":"Hebbar N, Epperly R, Vaidya A, Thanekar U, Moore SE, Umeda M, et al. CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells. Nat Commun. 2022;13:587.","journal-title":"Nat Commun"},{"key":"1544_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101422","volume":"5","author":"JT Zoine","year":"2024","unstructured":"Zoine JT, Immadisetty K, Ibanez-Vega J, Moore SE, Nevitt C, Thanekar U, et al. Peptide-scFv antigen recognition domains effectively confer CAR T cell multiantigen specificity. Cell Rep Med. 2024;5:101422.","journal-title":"Cell Rep Med"},{"key":"1544_CR61","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s00262-023-03422-6","volume":"72","author":"J Cheng","year":"2023","unstructured":"Cheng J, Ge T, Zhu X, Wang J, Zeng Y, Mu W, et al. Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia. Cancer Immunol Immunother. 2023;72:2331\u201346.","journal-title":"Cancer Immunol Immunother"},{"key":"1544_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1093750","volume":"14","author":"G Wu","year":"2023","unstructured":"Wu G, Guo S, Luo Q, Wang X, Deng W, Ouyang G, et al. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia. Front Immunol. 2023;14:1093750.","journal-title":"Front Immunol"},{"key":"1544_CR63","doi-asserted-by":"crossref","unstructured":"Kang AS, Johnson H, Lei N, Wong J, Razi N, Izgutdina A, et al. Bicistronic CAR T-cells against CD70 & active integrin \u03b22 overcome antigen heterogeneity and preserve safety in acute myeloid leukemia. bioRxiv:10.1101\/2025.09.21.677627v1 [Preprint]. 2025. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/2025.09.21.677627v1.","DOI":"10.1101\/2025.09.21.677627"},{"key":"1544_CR64","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1158\/2159-8290.CD-24-0096","volume":"14","author":"S Acharya","year":"2024","unstructured":"Acharya S, Basar R, Daher M, Rafei H, Li P, Uprety N, et al. CD28 costimulation augments CAR signaling in NK cells via the LCK\/CD3\u03b6\/ZAP70 signaling axis. Cancer Discov. 2024;14:1879\u2013900.","journal-title":"Cancer Discov"},{"key":"1544_CR65","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood.2020008221","volume":"138","author":"T Sauer","year":"2021","unstructured":"Sauer T, Parikh K, Sharma S, Omer B, Sedloev D, Chen Q, et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood. 2021;138:318\u201330.","journal-title":"Blood"},{"key":"1544_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101572","volume":"5","author":"B Caulier","year":"2024","unstructured":"Caulier B, Joaquina S, Gelebart P, Dowling TH, Kaveh F, Thomas M, et al. CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia. Cell Rep Med. 2024;5:101572.","journal-title":"Cell Rep Med"},{"key":"1544_CR67","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1158\/1535-7163.MCT-15-0067","volume":"14","author":"DS Pereira","year":"2015","unstructured":"Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, et al. AGS67E, an anti-CD37 monomethyl auristatin E antibody-drug conjugate as a potential therapeutic for B\/T-cell malignancies and AML: a new role for CD37 in AML. Mol Cancer Ther. 2015;14:1650\u201360.","journal-title":"Mol Cancer Ther"},{"key":"1544_CR68","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1182\/blood.V97.7.2121","volume":"97","author":"A Stucki","year":"2001","unstructured":"Stucki A, Rivier AS, Gikic M, Monai N, Schapira M, Spertini O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood. 2001;97:2121\u20139.","journal-title":"Blood"},{"key":"1544_CR69","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s43018-023-00652-6","volume":"4","author":"K Mandal","year":"2023","unstructured":"Mandal K, Wicaksono G, Yu C, Adams JJ, Hoopmann MR, Temple WC, et al. Structural surfaceomics reveals an AML-specific conformation of integrin \u03b22 as a CAR T cellular therapy target. Nat Cancer. 2023;4:1592\u2013609.","journal-title":"Nat Cancer"},{"key":"1544_CR70","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","volume":"7","author":"Y Kikushige","year":"2010","unstructured":"Kikushige Y, Shima T, Takayanagi S-i, Urata S, Miyamoto T, Iwasaki H, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010;7:708\u201317.","journal-title":"Cell Stem Cell"},{"key":"1544_CR71","doi-asserted-by":"publisher","first-page":"117388","DOI":"10.1016\/j.biopha.2024.117388","volume":"179","author":"KCS Pe","year":"2024","unstructured":"Pe KCS, Jewmoung S, Rad SMAH, Chantarat N, Chanswangphuwana C, Tashiro H, et al. Optimization of anti-TIM3 chimeric antigen receptor with CD8\u03b1 spacer and TNFR-based costimulation for enhanced efficacy in AML therapy. Biomed Pharmacother. 2024;179:117388.","journal-title":"Biomed Pharmacother"},{"key":"1544_CR72","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-20-0155","volume":"20","author":"WS Lee","year":"2021","unstructured":"Lee WS, Ye Z, Cheung AMS, Goh YPS, Oh HLJ, Rajarethinam R, et al. Effective killing of acute myeloid leukemia by TIM-3 targeted chimeric antigen receptor T cells. Mol Cancer Ther. 2021;20:1702\u201312.","journal-title":"Mol Cancer Ther"},{"key":"1544_CR73","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2458843","volume":"14","author":"X Zhang","year":"2025","unstructured":"Zhang X, Feng Z, Pranatharthi Haran A, Hua X. Dual nanobody-redirected and Bi-specific CD13\/TIM3 CAR T cells eliminate AML xenografts without toxicity to human HSCs. OncoImmunology. 2025;14:2458843.","journal-title":"OncoImmunology"},{"key":"1544_CR74","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1182\/bloodadvances.2021004424","volume":"5","author":"AJ Kaeding","year":"2021","unstructured":"Kaeding AJ, Barwe SP, Gopalakrishnapillai A, Ries RE, Alonzo TA, Gerbing RB, et al. Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia. Blood Adv. 2021;5:2350\u201361.","journal-title":"Blood Adv"},{"key":"1544_CR75","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1600-0609.2007.00928.x","volume":"79","author":"D Steinbach","year":"2007","unstructured":"Steinbach D, Onda M, Voigt A, Dawczynski K, Wittig S, Hassan R, et al. Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells. Eur J Haematol. 2007;79:281\u20136.","journal-title":"Eur J Haematol"},{"key":"1544_CR76","doi-asserted-by":"publisher","first-page":"5718","DOI":"10.1158\/1078-0432.CCR-21-1546","volume":"27","author":"Q Le","year":"2021","unstructured":"Le Q, Castro S, Tang T, Loeb AM, Hylkema T, McKay CN, et al. Therapeutic targeting of mesothelin with chimeric antigen receptor T cells in acute myeloid leukemia. Clin Cancer Res. 2021;27:5718\u201330.","journal-title":"Clin Cancer Res"},{"key":"1544_CR77","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00277-026-06742-6","volume":"105","author":"X Zhao","year":"2026","unstructured":"Zhao X, Ming X, Wu J, Zhu X, Xiao Y. Next-generation CAR-T therapy for acute myeloid leukemia: bridging innovation with clinical translation. Ann Hematol. 2026;105:20.","journal-title":"Ann Hematol"},{"key":"1544_CR78","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009013","volume":"12","author":"R Freeman","year":"2024","unstructured":"Freeman R, Shahid S, Khan AG, Mathew SC, Souness S, Burns ER, et al. Developing a membrane-proximal CD33-targeting CAR T cell. J Immunother Cancer. 2024;12:e009013.","journal-title":"J Immunother Cancer"},{"key":"1544_CR79","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 2020;10:702\u201323.","journal-title":"Cancer Discov"},{"key":"1544_CR80","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","volume":"13","author":"M Hamieh","year":"2023","unstructured":"Hamieh M, Mansilla-Soto J, Rivi\u00e8re I, Sadelain M. Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating. Cancer Discov. 2023;13:829\u201343.","journal-title":"Cancer Discov"},{"key":"1544_CR81","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1182\/blood.2022016033","volume":"140","author":"MH Kramer","year":"2022","unstructured":"Kramer MH, Zhang Q, Sprung R, Day RB, Erdmann-Gilmore P, Li Y, et al. Proteomic and phosphoproteomic landscapes of acute myeloid leukemia. Blood. 2022;140:1533\u201348.","journal-title":"Blood"},{"key":"1544_CR82","doi-asserted-by":"crossref","unstructured":"Herbrich S, Baran N, Cai T, Weng C, Aitken MJL, Post SM, et al. Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML. J Immunother Cancer. 2021;9:e002968.","DOI":"10.1136\/jitc-2021-002968"},{"key":"1544_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1145441","volume":"14","author":"L Tang","year":"2023","unstructured":"Tang L, Kong Y, Wang H, Zou P, Sun T, Liu Y, et al. Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia. Front Immunol. 2023;14:1145441.","journal-title":"Front Immunol"},{"key":"1544_CR84","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/s41375-025-02580-z","volume":"39","author":"K Marhelava","year":"2025","unstructured":"Marhelava K, Fidyt K, Pepek M, Krawczyk M, Forcados C, Malinowska A, et al. LILRB1-directed CAR-T cells for the treatment of hematological malignancies. Leukemia. 2025;39:1395\u2013411.","journal-title":"Leukemia"},{"key":"1544_CR85","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Amill L, Armand-Ug\u00f3n M, Val-Casals M, Mart\u00edn-Herreros B, \u00c1lamo JR, Pe\u00f1a S, et al. A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias. Leukemia. 2025.","DOI":"10.1038\/s41375-025-02705-4"},{"key":"1544_CR86","doi-asserted-by":"crossref","unstructured":"Koehne G, Mushtaq MU, Muffly LS, Menes M, Azzi J, Bernard L, et al. Remission of TP53-mutant AML after transplantation with Trem-Cel, a CRISPR\/Cas9 gene-edited allograft lacking CD33, followed by a donor-derived anti-CD33 chimeric antigen receptor T (VCAR33). JCO Precis Oncol. 2025;9:e2500556.","DOI":"10.1200\/PO-25-00556"},{"key":"1544_CR87","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1038\/s41375-025-02720-5","volume":"39","author":"R Kadirkamanathan","year":"2025","unstructured":"Kadirkamanathan R, Georgiadis C, Kloos A, Joshi A, Etuk A, Preece R, et al. Base edited \u201cuniversal\u201d donor CAR T-cell strategies for acute myeloid leukaemia. Leukemia. 2025;39:2978\u201387.","journal-title":"Leukemia"},{"key":"1544_CR88","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3389\/fonc.2019.00241","volume":"9","author":"S Di","year":"2019","unstructured":"Di S, Zhou M, Pan Z, Sun R, Chen M, Jiang H, et al. Combined adjuvant of Poly I:C improves antitumor effects of CAR-T cells. Front Oncol. 2019;9:241.","journal-title":"Front Oncol"},{"key":"1544_CR89","first-page":"2111","volume":"109","author":"HE Ramsey","year":"2024","unstructured":"Ramsey HE, Gorska AE, Smith BN, Monteith AJ, Fuller L, Arrate MP, et al. TLR3 agonism augments CD47 inhibition in acute myeloid leukemia. Haematologica. 2024;109:2111\u201321.","journal-title":"Haematologica"},{"key":"1544_CR90","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.3390\/cancers17243892","volume":"17","author":"A Segura Tudela","year":"2025","unstructured":"Segura Tudela A, Geller R, Paiva B, Torres S\u00e1nchez SC, Gonz\u00e1lez Romero E, Lloret Madrid P, et al. The rise of fine-tuned CAR-based therapies against acute myeloid leukemia. Cancers. 2025;17:3892.","journal-title":"Cancers"},{"key":"1544_CR91","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1182\/blood.2023023210","volume":"145","author":"HJ Silva","year":"2025","unstructured":"Silva HJ, Martin G, Birocchi F, Wehrli M, Kann MC, Supper V, et al. CD70 CAR T cells secreting an anti-CD33\/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML. Blood. 2025;145:720\u201331.","journal-title":"Blood"},{"key":"1544_CR92","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood.2019002779","volume":"135","author":"X He","year":"2020","unstructured":"He X, Feng Z, Ma J, Ling S, Cao Y, Gurung B, et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood. 2020;135:713\u201323.","journal-title":"Blood"},{"key":"1544_CR93","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011887","volume":"13","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zheng X, Wang Z, Xiao Z, Lin Y, Zhang F, et al. CD33KO-CD33-mesothelin Loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemia. J Immunother Cancer. 2025;13:e011887.","journal-title":"J Immunother Cancer"},{"key":"1544_CR94","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.4049\/jimmunol.1200796","volume":"189","author":"J Hilpert","year":"2012","unstructured":"Hilpert J, Grosse-Hovest L, Gr\u00fcnebach F, Buechele C, Nuebling T, Raum T, et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol. 2012;189:1360\u201371.","journal-title":"J Immunol"},{"key":"1544_CR95","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","volume":"7","author":"SH Baumeister","year":"2019","unstructured":"Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, et al. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma. Cancer Immunol Res. 2019;7:100\u201312.","journal-title":"Cancer Immunol Res"},{"key":"1544_CR96","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/gt.2010.21","volume":"17","author":"S Peinert","year":"2010","unstructured":"Peinert S, Prince HM, Guru PM, Kershaw MH, Smyth MJ, Trapani JA, et al. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther. 2010;17:678\u201386.","journal-title":"Gene Ther"},{"key":"1544_CR97","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","volume":"26","author":"C Riether","year":"2020","unstructured":"Riether C, Pabst T, H\u00f6pner S, Bacher U, Hinterbrandner M, Banz Y, et al. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020;26:1459\u201367.","journal-title":"Nat Med"},{"key":"1544_CR98","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000431062","volume":"89","author":"Y Kikushige","year":"2015","unstructured":"Kikushige Y, Miyamoto T. Identification of TIM-3 as a leukemic stem cell surface molecule in primary acute myeloid leukemia. Oncology. 2015;89:28\u201332.","journal-title":"Oncology"},{"key":"1544_CR99","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70155","volume":"9","author":"JJ van der Schans","year":"2025","unstructured":"van der Schans JJ, Vishwasrao P, Poels R, Antti M, Wang Z, Quik M, et al. Surface downmodulation of TIM3 safeguards healthy cells but not acute myeloid leukemia from CAR T-cell therapy. Hemasphere. 2025;9:e70155.","journal-title":"Hemasphere"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01544-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01544-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01544-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T03:11:03Z","timestamp":1788145863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01544-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1544"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01544-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"144"}}